Stomach Cancer Treatment Market Worth $11.2 Billion By 2030

Stomach Cancer Treatment Market Growth & Trends

The global stomach cancer treatment market size is expected to reach USD 11.2 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 12.9% from 2022 to 2030. Increasing uptake of immunotherapy and targeted therapy, coupled with the launch of new drugs, is expected to fuel growth.

According to Globocan, the incidence of gastric cancer in 2020 was around 1.1 million, which is expected to increase to 1.42 million by 2030. Increasing knowledge regarding the molecular basis of the disease has led to a rise in the number of targeted drugs and immunotherapy drugs being developed and launched in the market. HER-2 targeted drugs such as Herceptin have been available in the market since 2010. Another targeted drug, Cyramza, which is a VEGF-targeting monoclonal antibody, has been available since 2014. EGFR and PD-1 targeted drugs and immunotherapies are currently being developed for the treatment of gastric cancer.

The approval and subsequent launch of drugs in the clinical pipeline are also expected to drive the gastric cancer therapy market. For instance, in March 2021, the NMPA approved Eli Lilly and Innovent Biologics’ drug Sintilimab, a PD-1 inhibitor, for the treatment of gastric or gastroesophageal junction adenocarcinoma in China. Furthermore, in May 2020, the U.S. FDA granted the orphan drug designation to Enhertu for the treatment of gastric cancers. Subsequently, in January 2021, the U.S. FDA approved Enhertu for the treatment of advanced or metastatic forms of the disease.

Patent expiry of key drugs such as Herceptin and subsequent launch of biosimilars are expected to restrain the growth of the gastric cancer therapy market. Additionally, lesser adoption of targeted therapy due to high costs might hamper the growth of the market. For instance, Cyramza was not considered cost-effective as compared to other drugs. It was rejected by NICE due to a lack of cost-effectiveness in England. Furthermore, the product was rejected for reimbursement in France due to a lack of additional benefits compared to the clinically relevant comparators.

 Request a free sample copy or view report summary: Stomach Cancer Treatment Market Report

Stomach Cancer Treatment Market Report Highlights

• The targeted therapy treatment type segment held the second-largest revenue share in 2021 due to the robust clinical pipeline and approval of new products. For instance, in January 2021, the U.S. FDA approved Enhertu for the treatment of patients with metastatic or locally advanced HER-2 positive gastric cancers

• By treatment type, immunotherapy is anticipated to witness the fastest growth during the forecast period due to the launch and adoption of PD-1 inhibitors such as Opdivo and Keytruda in the gastric cancer therapy market

• By disease indication, the gastric cancer/gastroesophageal junction cancer segment is expected to maintain its lead during the forecast period due to the high prevalence of the disease and the availability of various products. The gastrointestinal stromal tumors (GISTs) segment is expected to grow due to the increasing number of product launches

• Based on the distribution channel, the specialty and retail pharmacies segment dominated the gastric cancer therapy market in 2021. Targeted and immunotherapy drugs often have special requirements in terms of storage and logistics and are therefore distributed by specialty pharmacies

• Asia Pacific is expected to maintain its dominance during the forecast period due to the high disease burden and research initiatives in the region. According to a Globocan report, Asia accounts for around 75.3% of all new cases of gastric cancer in 2020

• Europe is anticipated to witness considerable growth during the forecast period owing to the increasing target patient population and approval of targeted and immunotherapy drugs

Stomach Cancer Treatment Market Segmentation

Grand View Research has segmented the global stomach cancer treatment market on the basis of treatment type, disease indication, route of administration, drug class, distribution channel, and region:

Stomach Cancer Treatment Type Outlook (Patient Share, (%); Revenue, USD Million, 2018 - 2030)

• Chemotherapy

• Immunotherapy

• Targeted Therapy

• Radiation Therapy And Surgery (Qualitative Analysis Only)

Stomach Cancer Treatment Disease Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Gastric Cancer/Gastroesophageal Junction Cancer

• Gastrointestinal Stromal Tumors

Stomach Cancer Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Injectable

Stomach Cancer Treatment Drug Class Outlook (Patient Share, (%); Revenue, USD Million, 2018 - 2030)

• PD-1/PD-L1 Inhibitors

• HER2 Antagonists

• VEGFR2 Antagonists

• Others

Stomach Cancer Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Specialty & Retail Pharmacies

• Others

Stomach Cancer Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Spain

  • Italy

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

List of Key Players in the Stomach Cancer Treatment Market

• Novartis AG

• Pfizer, Inc.

• Mylan N.V.

• F. Hoffmann La Roche Ltd.

• Eli Lilly And Company

• Merck & Co., Inc.

• Teva Pharmaceutical Industries Ltd.

• Celltrion Healthcare Co., Ltd.

• Samsung Bioepis

• Bristol Myers Squibb Company